study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
MH-GABA-NEURO_01,2017,randomized controlled trial,SMD,-0.2908,-0.4238,-0.1577,62,48,low,10.3389/fnins.2020.00923,mental_health_journal,acute_stress,Adults with acute stress concerns,None reported,9
MH-GABA-NEURO_02,2018,randomized controlled trial,SMD,-0.3666,-0.5188,-0.2143,66,51,some concerns,10.3390/nu16050608,mental_health_journal,acute_stress,Adults with acute stress concerns,Mild GI discomfort,10
MH-GABA-NEURO_03,2019,randomized controlled trial,SMD,-0.4099,-0.5435,-0.2763,70,54,mixed,10.1080/13880209.2018.1557698,mental_health_journal,acute_stress,Adults with acute stress concerns,Transient headache,11
